Sansure Biotech of Changsha raised $77M in a funding round led by Lilly Asia Ventures and Highlight Capital with participation from June Capital.
Sansure Biotech of Changsha, a molecular diagnostics company, raised $77 Million in a funding round led by Lilly Asia Ventures and Highlight Capital with participation from June Capital. Sansure provides innovative molecular diagnosis and genetic testing kits and tools to diagnostic labs and researchers. It makes nucleic acid extraction kits, real time polymerase chain reaction (PCR) diagnostic and research kits and fluorescence systems. Sansure claims to be the second-largest China company in its market niche.
